Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Alexandra Schäfer, David R. Martinez, John J. Won, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 643
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
Zhujun Cao, Weiyi Gao, Hong Bao, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 5, pp. 406-417
Open Access | Times Cited: 187
SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
Kenneth H. Dinnon, Sarah R. Leist, Kenichi Okuda, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 664
Open Access | Times Cited: 92
Bioinspired oral delivery devices
Xiaoxuan Zhang, Guopu Chen, Hui Zhang, et al.
Nature Reviews Bioengineering (2023) Vol. 1, Iss. 3, pp. 208-225
Open Access | Times Cited: 46
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
Jared Pitts, Jiani Li, Jason K. Perry, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 6
Open Access | Times Cited: 60
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Zhonglei Wang, Liyan Yang, Xian-qing Song
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination
Lily E. Adams, Sarah R. Leist, Kenneth H. Dinnon, et al.
Cell Reports (2023) Vol. 42, Iss. 4, pp. 112326-112326
Open Access | Times Cited: 35
Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
Sheli R. Radoshitzky, Patrick L. Iversen, Xianghan Lu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
Richard L. Mackman, Rao Kalla, Darius Babusis, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 11701-11717
Open Access | Times Cited: 29
Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies
Shuiyun Lan, Grace Neilsen, Ryan L. Slack, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 22
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
Liu Cao, Yingjun Li, Sidi Yang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 661
Open Access | Times Cited: 29
Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
Yuan‐Qin Min, Wei Xiong, Wei Shen, et al.
Science Advances (2024) Vol. 10, Iss. 15
Open Access | Times Cited: 6
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses
David R. Martinez, Fernando R. Moreira, Nicholas Catanzaro, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 748
Open Access | Times Cited: 5
The impact of remdesivir on SARS-CoV-2 evolution in vivo
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, et al.
JCI Insight (2025)
Open Access
Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection
Bryce M. Warner, Robert Vendramelli, Amrit S. Boese, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0316952-e0316952
Open Access
Active microgel particle swarms for intrabronchial targeted delivery
Hui Chen, Junhui Law, Yibin Wang, et al.
Science Advances (2025) Vol. 11, Iss. 11
Closed Access
Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro
Hulda R. Jónsdóttir, Denise Siegrist, Thomas Julien, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 113058-113058
Open Access | Times Cited: 22
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges
Xiao‐Ying Xu, Yuheng Chen, Xinyu Lu, et al.
Biochemical Pharmacology (2022) Vol. 205, pp. 115279-115279
Open Access | Times Cited: 22
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Xiaoman Li, Yongbing Pan, Qiangling Yin, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 18
Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential
David R. Martinez, Fernando R. Moreira, Mark R. Zweigart, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 10
Antiviral drug recognition and elevator-type transport motions of CNT3
Nicholas J. Wright, Feng Zhang, Yang Suo, et al.
Nature Chemical Biology (2024) Vol. 20, Iss. 9, pp. 1144-1153
Closed Access | Times Cited: 3
Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
Rana Abdelnabi, Piet Maes, Steven De Jonghe, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top